Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
March Altus Capital Management LP (CIK 1574661) reported $16.0M across 11 reported positions in its SEC 13F filing for 2016-09-30. Largest positions: EW ($4.2M, 26.11%), ACAD ($2.3M, 14.47%), PETX ($2.0M, 12.79%), JNJ ($1.5M, 9.61%), DXCM ($1.2M, 7.79%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | EW | EDWARDS LIFESCIENCES CORP | $4.2M | 26.11% | 34,611 | Added |
| 2 | ACAD | ACADIA PHARMACEUTICALS INC | $2.3M | 14.47% | 72,723 | Trimmed |
| 3 | PETX | ARATANA THERAPEUTICS INC | $2.0M | 12.79% | 218,515 | Hold |
| 4 | JNJ | JOHNSON & JOHNSON | $1.5M | 9.61% | 13,000 | Hold |
| 5 | DXCM | DEXCOM INC | $1.2M | 7.79% | 14,200 | Added |
| 6 | LLY | LILLY ELI & CO | $1.1M | 6.68% | 13,310 | Trimmed |
| 7 | TSRO | TESARO INC | $1.0M | 6.27% | 10,000 | New |
| 8 | ZTS | ZOETIS INC | $827,000 | 5.17% | 15,900 | New |
| 9 | BIIB | BIOGEN INC | $814,000 | 5.09% | 2,600 | New |
| 10 | ALXN | ALEXION PHARMACEUTICALS INC | $760,000 | 4.75% | 6,199 | Trimmed |
| 11 | REGN | REGENERON PHARMACEUTICALS | $201,000 | 1.26% | 500 | New |
| 12 | ALGN | ALIGN TECHNOLOGY INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2016-09-30